New Shanghai Business University Health Private Board
In recent years, 'going global' has become a keyword in China's innovative drug industry, with more and more Chinese innovative pharmaceutical companies embarking on a new journey of internationalization. In the context of the rapidly changing pharmaceutical industry environment, how to layout an overseas strategy has become a common topic for innovative pharmaceutical companies.
4month12Today, in response to Frost & SullivanFrost & SullivanAt the invitation of Dr. Wang Xin, Global Partner and President of Greater China at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), the seventh session of the New Shanghai Business Leaders' Private Equity Directors' Meeting was successfully held at the Frost & Sullivan China headquarters on "Breaking the deadlock “involutionary competition”, racing “going global”" In the theme of "Frost & Sullivan's Decision-Makers on Innovative Drugs Going Global", focusing on new directions in cooperation for innovative drugs going global, six heavyweight guests from biomedical enterprises including Aimephi, Shanghai Cell Therapy Group, Fosun Kite, Heptaresis Biopharma, Heyuan Bio and Lixin Pharmaceutical attended the meeting. The meeting also invited industry experts from nine institutions including the Shanghai Biomedical Science and Technology Development Center, CITIC Securities, Ernst & Young, Jindu Law Firm, Bilibili Venture Capital, PowerSquare Fund, CICC Capital, Zhongyong Financial Holdings and Fenglin Group to share their forward-looking insights on the commercialization of innovative drugs, demonstrating from multiple dimensions that Frost & Sullivan's Healthcare Business Unit has professional capabilities and rich experience in the field of life sciences.
Global Partner and President, Greater China at Frost & Sullivan Dr. Wang Xin
At the meeting, Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China, expressed gratitude for the organization of the New Shanghai Businessmen's Federation. He warmly welcomed the entrepreneurs and guests present and focused on the theme of Frost & Sullivan's empowerment of biopharmaceutical enterprise investment and financing. He provided a detailed introduction to Frost & Sullivan's consulting services in Greater China, the core strengths of Frost & Sullivan's investment and financing services in the healthcare industry, and the 'New Investment' concept.
Dr. Wang Xin stated that capital investment is an indispensable and important factor in driving the growth of biopharmaceutical companies, and it is crucial for promoting research and development and accelerating commercial success in the life sciences industry. This year marks the 50th anniversary of Frost & Sullivan's global establishment.62The anniversary is also the first time we have entered the Chinese market25On its anniversary, Frost & Sullivan has always been committed to helping businesses grow. It deeply engages in the global capital markets and corporate consulting services, providing businesses with comprehensive investment and financing as well as various other professional consulting services. As a global growth consulting company, In the future, Frost & Sullivan hopes to join hands with LeadLeo, cloud technology, Yixin, and YUAN CAPITAL, along with many professional institutions, to create an ecological service system covering the entire lifecycle and industrial chain of enterprises. This system aims to help biopharmaceutical companies achieve growth and empower the transformation and upgrading of the biopharmaceutical industry.
Dr. Wang Xin looks forward to sharing through this private board meeting with more leading biopharmaceutical companies, high-quality capital, and outstanding partners. We will delve into new trends in biopharmaceutical investment and financing, explore cutting-edge investment opportunities, jointly explore the successful path for biopharmaceutical companies in the capital market, and contribute to the development of innovative drugs in China!
Partner and Managing Director, Greater China, Frost & Sullivan fattening
Frost & Sullivan's Partner and Managing Director of Healthcare Business in Greater China, Mao Hua, presented 'China BiopharmaceuticalsLicense-out of the MainlandDevelopment and Strategy Research' theme sharing. Mao Hua briefly introduced the current situation and development trends of the innovative drug industry, and discussed pharmaceutical companiesLicense-out of the MainlandThe opportunities and challenges of the model are analyzed. He pointed out that in recent years, factors such as enhanced R&D capabilities for innovative drugs, great potential in overseas markets, gradual integration at home and abroad, and domestic pressure to reduce prices for innovative drugs have driven Chinese pharmaceutical companies to go global, actively explore international market territories, and biopharmaceutical enterprises continue toLicense-out of the MainlandTransactions bring domestic technology abroad, and by collaborating with multinational enterprises, we can better participate in global competition. License-out of the MainlandThe model holds strategic significance for enterprises as it boosts valuation (endorsement), can serve as the main business model, and a source of R&D funds. However, on the other hand,License-out of the MainlandThe model also faces challenges such as low enterprise valuation, limited cooperation rights and interests, restricted transaction implementation, and high operational difficulties.
Partner and Managing Director of Frost & Sullivan Greater China Region Yang Xiaocheng
Chairman and President of Shanghai Cell Therapy Group Qian Qijun
Co-Head of Investment Banking Healthcare Group and Managing Director of CITIC Securities Liu Xiaolan
Chairman of Aimebio Professor Fan Guohuang
General Manager of Harmony Biosciences China Wu Minghua
General Manager of Fenglin Group Wang Bo
Vice President of Strategy and Business Development, Lixin Pharmaceutical Wang Yufeng
Executive Director of PowerSquare Fund Hu Hongdan
EY partner Li Dongxu
CICC Capital Dr. Zhao Xinhao
Partner at King & Dun Law Firm Xu Hui
Fosun KiteCEOYellow Sea
Director of Shanghai Biomedical Science and Technology Development Center, Deputy Secretary of the Party Committee Li Jizong
Director of Shanghai Cell Therapy Group Susuoliang
Secretary of the Board of Directors and Deputy Director of the President's Office of Shanghai Cell Therapy Group Jiang Xiaofen
General Manager of Zhongyong Jinkong Liu Yu
Binlin Venture Capital Management Partner Sun Xiaolu
Binlin Star Venture Capital Operation Director Wang Qian
General Manager of Operations, New Shanghai Business Federation Wang Jian
Wu Minghua, General Manager of Harmony Pharma China, and Wang Yufeng, Vice President of Strategy and Business Development at Lixin Pharmaceutical, shared their experiences with overseas licensing in turn. They pointed out that with continuous policy reinforcement, the iteration and upgrading of new pharmaceutical R&D technologies, and the evolution of the global commercialization landscape, internationalization is an inevitable path for local leading pharmaceutical companies. Currently, it is an excellent time to promote innovative drugs overseas. Domestic innovative drugs going global require companies to be familiar with the rules and requirements for overseas listing. A clear global R&D strategy and real-time updates on the R&D progress of similar drugs can help companies accelerate their overseas expansion and build global influence.
This private board meeting was chaired by Ms. Li Xiaoyan, Deputy Secretary-General of the New Shanghai Business Federation. The atmosphere at the scene was lively, with all parties expressing their opinions freely. The participating guests offered rich forward-looking insights on how enterprises can layout and plan to achieve high-value overseas transactions, analyzed the biggest challenges and difficulties for Chinese pharmaceutical companies going global, and fully discussed and exchanged views on the highlights and trends of future Chinese pharmaceutical companies' overseas expansion.
The meeting was chaired by Li Xiaoyan, Deputy Secretary-General of the New Shanghai Business Federation.
